|
CBD FOR ACNE |
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes |
|
CBD FOR ACNE |
The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities |
|
CBD FOR ACNE |
Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling |
|
CBD FOR ACNE |
Endocannabinoid signaling and epidermal differentiation |
|
CBD FOR ADD / ADHD |
Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats |
|
CBD FOR ADD / ADHD |
Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use |
|
CBD FOR ADD / ADHD |
Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students |
|
CBD FOR ADD / ADHD |
Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report |
|
CBD FOR ADD / ADHD |
Fitness to drive in spite (because) of THC |
|
CBD FOR ADDICTION |
Cannabidiol inhibits the reward-facilitating effect of morphine |
|
CBD FOR ADDICTION |
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances |
|
CBD FOR ADDICTION |
Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats |
|
CBD FOR ADDICTION |
Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment |
|
CBD FOR ADDICTION |
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 |
|
CBD FOR ADDICTION |
Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents |
|
CBD FOR ADDICTION |
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity |
|
CBD FOR ADDICTION |
Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder |
|
CBD FOR ADDICTION |
Cannabidiol for the treatment of cannabis withdrawal syndrome |
|
CBD FOR ALS |
ALS: delayed disease progression in mice by treatment with a cannabinoid |
|
CBD FOR ALS |
The (Endo)Cannabinoid System in Multiple Sclerosis and ALS |
|
CBD FOR ALS |
Survey of cannabis use in patients with ALS |
|
CBD FOR ALZHEIMERS |
Endocannabinoid signalling in Alzheimer’s disease |
|
CBD FOR ALZHEIMERS |
A molecular link between the active component of marijuana and Alzheimer’s disease pathology |
|
CBD FOR ALZHEIMERS |
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells |
|
CBD FOR ALZHEIMERS |
The Potential Therapeutic Effects of THC on Alzheimer’s Disease |
|
CBD FOR ALZHEIMERS |
The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease |
|
CBD FOR ALZHEIMERS |
Cannabinoids for the treatment of dementia |
|
CBD FOR ALZHEIMERS |
Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression |
|
CBD FOR ALZHEIMERS |
Cannabidiol: A promising drug for neurodegenerative disorders? |
|
CBD FOR ALZHEIMERS |
Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition |
|
CBD FOR ALZHEIMERS |
The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses |
|
CBD FOR ALZHEIMERS |
The role of phytochemicals in the treatment and prevention of dementia |
|
CBD FOR ALZHEIMERS |
Cannabinoids for the treatment of dementia |
|
CBD FOR ALZHEIMERS |
Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement |
|
CBD FOR ALZHEIMERS |
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic |
|
CBD FOR ALZHEIMERS |
Can Marijuana Prevent Alzheimer’s? |
|
CBD FOR ANOREXIA |
The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence |
|
CBD FOR ANOREXIA |
Cancer cachexia and cannabinoids |
|
CBD FOR ANOREXIA |
Brain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa |
|
CBD FOR ANXIETY |
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa |
|
CBD FOR ANXIETY |
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients |
|
CBD FOR ANXIETY |
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder |
|
CBD FOR ANXIETY |
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation |
|
CBD FOR ANXIETY |
Effects of cannabidiol (CBD) on regional cerebral blood flow |
|
CBD FOR ANXIETY |
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors |
|
CBD FOR ANXIETY |
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system |
|
CBD FOR ANXIETY |
Plant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence |
|
CBD FOR ATHEROSCLEROSIS |
Cannabinoid receptors in atherosclerosis |
|
CBD FOR ATHEROSCLEROSIS |
The potential use of cannabidiol in the therapy of metabolic syndrome |
|
CBD FOR ATHEROSCLEROSIS |
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice |
|
CBD FOR ARTHRITIS |
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis |
|
CBD FOR ARTHRITIS |
The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55 |
|
CBD FOR ARTHRITIS |
Arthritis and cannabinoids |
|
CBD FOR ASTHMA |
Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma |
|
CBD FOR ASTHMA |
Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs |
|
CBD FOR ASTHMA |
Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways |
|
CBD FOR ASTHMA |
Bronchodilator effect of delta1-tetrahydrocannabinol |
|
CBD FOR AUTISM |
Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders |
|
CBD FOR AUTISM |
A novel approach to the symptomatic treatment of autism |
|
CBD FOR AUTISM |
Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders |
|
CBD FOR AUTISM |
Targeting the endocannabinoid system in the treatment of fragile X syndrome |
|
CBD FOR BIPOLAR AFFECTIVE DISORDER |
Cannabidiol was ineffective for manic episode of bipolar affective disorder |
|
CBD FOR BIPOLAR AFFECTIVE DISORDER |
Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania |
|
CBD FOR BIPOLAR AFFECTIVE DISORDER |
Does Cannabis Use Affect Treatment Outcome in Bipolar Disorder?: A Longitudinal Analysis |
|
CBD FOR BIPOLAR AFFECTIVE DISORDER |
The Use of Cannabis as a Mood Stabilizer in Bipolar Disorder: Anecdotal Evidence and the Need for Clinical Research |
|
CBD FOR CANCER - GENERAL |
Cannabidiol inhibits angiogenesis by multiple mechanisms |
|
CBD FOR CANCER - GENERAL |
The inhibitory effects of cannabidiol on systemic malignant tumors |
|
CBD FOR CANCER - GENERAL |
Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 |
|
CBD FOR CANCER - GENERAL |
Marijuana fights cancer and helps manage side effects |
|
CBD FOR CANCER - LUNG |
COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells |
|
CBD FOR CANCER - LUNG |
Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells |
|
CBD FOR CANCER - LUNG |
Media ignored expert’s shocking findings that marijuana helps prevent lung cancer |
|
CBD FOR CANCER - PROSTATE/COLON |
In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines |
|
CBD FOR CANCER - PROSTATE/COLON |
Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent |
|
CBD FOR CANCER - PROSTATE/COLON |
Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer |
|
CBD FOR CANCER - PROSTATE/COLON |
Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol |
|
CBD FOR CANCER - BREAST |
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy |
|
CBD FOR CANCER - BREAST |
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis |
|
CBD FOR CANCER - BREAST |
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells |
|
CBD FOR CANCER - BREAST |
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration |
|
CBD FOR CANCER - BRAIN |
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines(PubMed) |
|
CBD FOR CANCER - BRAIN |
Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas |
|
CBD FOR CANCER - BRAIN |
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism |
|
CBD FOR CANCER - BRAIN |
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target |
|
CBD FOR CANCER - BRAIN |
Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents |
|
CBD FOR CANCER - BRAIN |
Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect |
|
CBD FOR CANCER - BRAIN |
Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme |
|
CBD FOR CANCER - LEUKEMIA |
Cannabidiol-Induced Apoptosis in Human Leukemia Cells |
|
CBD FOR CANCER - LEUKEMIA |
Cannabidiol Reduces Leukemic Cell Size – But Is It Important? |
|
CBD FOR CANCER - LEUKEMIA |
Targeting cannabinoid receptors to treat leukemia |
|
CBD FOR CANCER - SKIN |
Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed) |
|
CBD FOR CANCER - SKIN |
Cannabinoid receptors as novel targets for the treatment of melanoma |
|
CBD FOR CANCER - SKIN |
The Cannabinoid Receptors Are Required for Ultraviolet-Induced Inflammation and Skin Cancer Development |
|
CBD FOR CANCER - ENDOCRINE |
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells |
|
CBD FOR CANCER - ENDOCRINE |
Cannabinoids in pancreatic cancer: Correlation with survival and pain |
|
CBD FOR CANCER - ENDOCRINE |
Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma |
|
CBD FOR CANCER - BLADDER |
Association Between Cannabis Use and the Risk of Bladder Cancer |
|
CBD FOR CANCER - BLADDER |
Inhibitory Effect of Standardized Cannabis sativaExtract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility |
|
CBD FOR CANCER - BLADDER |
Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism |
|
CBD FOR CANCER - PAIN RELIEF |
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial |
|
CBD FOR CANCER - PAIN RELIEF |
Marijuana extract helps prevent chemo pain |
|
CBD FOR CANCER - PAIN RELIEF |
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics |
|
CBD FOR CROHNS & COLITIS |
Cannabis finds its way into treatment of Crohn’s disease |
|
CBD FOR CROHNS & COLITIS |
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis |
|
CBD FOR CROHNS & COLITIS |
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis |
|
CBD FOR CROHNS & COLITIS |
The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis |
|
CBD FOR CROHNS & COLITIS |
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice |
|
CBD FOR CROHNS & COLITIS |
Cannabinoids and the gut: New developments and emerging concepts |
|
CBD FOR CROHNS & COLITIS |
Endocannabinoids and the gastrointestinal tract |
|
CBD FOR CROHNS & COLITIS |
Cannabinoids and gastrointestinal motility: Animal and human studies |
|
CBD FOR CROHNS & COLITIS |
Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis |
|
CBD FOR DEPRESSION |
Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa |
|
CBD FOR DEPRESSION |
The endocannabinoid system and the treatment of mood and anxiety disorders |
|
CBD FOR DEPRESSION |
Endocannabinoid signaling in the etiology and treatment of major depressive illness |
|
CBD FOR DEPRESSION |
Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors |
|
CBD FOR DEPRESSION |
Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants |
|
CBD FOR DEPRESSION |
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa |
|
CBD FOR DEPRESSION |
Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress |
|
CBD FOR DEPRESSION |
Serum contents of endocannabinoids are correlated with blood pressure in depressed women |
|
CBD FOR DEPRESSION |
The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants |
|
CBD FOR DEPRESSION |
Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures |
|
CBD FOR ENDOCRINE DISORDERS |
The emerging role of the endocannabinoid system in endocrine regulation and energy balance |
|
CBD FOR ENDOCRINE DISORDERS |
Endocannabinoids in endocrine and related tumours |
|
CBD FOR ENDOCRINE DISORDERS |
Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas |
|
CBD FOR ENDOCRINE DISORDERS |
The role of the endocannabinoid system in the neuroendocrine regulation of energy balance |
|
CBD FOR ENDOCRINE DISORDERS |
CBD for children with Dravet’s and intractable seizures |
|
CBD FOR ENDOCRINE DISORDERS |
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy |
|
CBD FOR ENDOCRINE DISORDERS |
Medicinal marijuana stops seizures, brings hope to a little girl |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabinoids for epilepsy |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabis, cannabidiol, and epilepsy – From receptors to clinical response |
|
CBD FOR ENDOCRINE DISORDERS |
The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability |
|
CBD FOR ENDOCRINE DISORDERS |
Chronic administration of cannabidiol to healthy volunteers and epileptic patients |
|
CBD FOR ENDOCRINE DISORDERS |
Endocannabinoid system protects against cryptogenic seizures |
|
CBD FOR ENDOCRINE DISORDERS |
Seizing an opportunity for the endocannabinoid system |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabidiol: promise and pitfalls |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabidivarin (CBDV) suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo |
|
CBD FOR ENDOCRINE DISORDERS |
Hypnotic and antiepileptic effects of cannabidiol |
|
CBD FOR ENDOCRINE DISORDERS |
The cannabinoids as potential antiepileptics |
|
CBD FOR ENDOCRINE DISORDERS |
Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats |
|
CBD FOR FIBROMYALGIA |
Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life |
|
CBD FOR FIBROMYALGIA |
Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia |
|
CBD FOR FIBROMYALGIA |
Cannabinoids for fibromyalgia |
|
CBD FOR FIBROMYALGIA |
Medical Cannabis for the Treatment of Fibromyalgia |
|
CBD FOR GLAUCOMA |
Cannabinoids and glaucoma |
|
CBD FOR GLAUCOMA |
The treatment of glaucoma using a non-psychoactive preparation of Cannabis sativa |
|
CBD FOR GLAUCOMA |
Cannabinoids for treatment of glaucoma |
|
CBD FOR HEART DISEASE |
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion |
|
CBD FOR HEART DISEASE |
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy |
|
CBD FOR HEART DISEASE |
The Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors |
|
CBD FOR HEART DISEASE |
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury |
|
CBD FOR HEART DISEASE |
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension |
|
CBD FOR HEART DISEASE |
Oleamide: A fatty acid amide signaling molecule in the cardiovascular system? |
|
CBD FOR HUNTINGTONS DISEASE |
Cannabinoids: Novel medicines for the treatment of Huntington’s disease |
|
CBD FOR HUNTINGTONS DISEASE |
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors |
|
CBD FOR HUNTINGTONS DISEASE |
Controlled clinical trial of cannabidiol in Huntington’s disease |
|
CBD FOR HUNTINGTONS DISEASE |
Prospects for cannabinoid therapies in basal ganglia disorders |
|
CBD FOR HUNTINGTONS DISEASE |
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice |
|
CBD FOR INFLAMMATION |
The endocannabinoid system: an emerging key player in inflammation |
|
CBD FOR INFLAMMATION |
Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice |
|
CBD FOR INFLAMMATION |
Cannabinoids, endocannabinoids, and related analogs in inflammation |
|
CBD FOR INFLAMMATION |
Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor |
|
CBD FOR INFLAMMATION |
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors |
|
CBD FOR INFLAMMATION |
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis |
|
CBD FOR INFLAMMATION |
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation |
|
CBD FOR INFLAMMATION |
Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement |
|
CBD FOR INFLAMMATION |
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption |
|
CBD FOR INFLAMMATION |
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation |
|
CBD FOR INFLAMMATION |
Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death |
|
CBD FOR INFLAMMATION |
Cannabinoids in clinical practice |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Therapeutic potential of cannabinoid-based drugs |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology) |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Cannabinoids and the gut: New developments and emerging concepts |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Endocannabinoids and the gastrointestinal tract |
|
CBD FOR IRRITABLE BOWEL SYNDROME |
Cannabinoids and gastrointestinal motility: Animal and human studies |
|
CBD FOR KIDNEY DISEASE |
Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay |
|
CBD FOR KIDNEY DISEASE |
Is There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease? |
|
CBD FOR KIDNEY DISEASE |
The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases |
|
CBD FOR LIVER DISEASE |
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death |
|
CBD FOR LIVER DISEASE |
Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis |
|
CBD FOR LIVER DISEASE |
Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats |
|
CBD FOR LIVER DISEASE |
Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol |
|
CBD FOR LIVER DISEASE |
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice |
|
CBD FOR LIVER DISEASE |
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation |
|
CBD FOR METABOLIC SYNDROME |
The potential use of cannabidiol in the therapy of metabolic syndrome |
|
CBD FOR METABOLIC SYNDROME |
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes |
|
CBD FOR METABOLIC SYNDROME |
Metabolic syndrome in people with a psychotic illness: is cannabis protective? |
|
CBD FOR METABOLIC SYNDROME |
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome |
|
CBD FOR MIGRAINES |
Effects of anandamide in migraine: data from an animal model |
|
CBD FOR MIGRAINES |
Cannabinoids and hallucinogens for headache |
|
CBD FOR MIGRAINES |
The endocannabinoid system and migraine |
|
CBD FOR MIGRAINES |
Variations in the cannabinoid receptor 1 gene predispose to migraine |
|
CBD FOR MOOD DISORDERS |
The endocannabinoid system and the treatment of mood and anxiety disorders |
|
CBD FOR MOOD DISORDERS |
The endocannabinoid system and psychiatric disorders |
|
CBD FOR MOOD DISORDERS |
The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives |
|
CBD FOR MOOD DISORDERS |
Endocannabinoid system dysfunction in mood and related disorders |
|
CBD FOR MOOD DISORDERS |
Effects of cannabidiol (CBD) on regional cerebral blood flow |
|
CBD FOR MOTION SICKNESS |
Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system |
|
CBD FOR MOTION SICKNESS |
The Effects of Cannabidiol and Tetrahydrocannabinol on Motion‐Induced Emesis |
|
CBD FOR MULTIPLE SCLEROSIS |
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis |
|
CBD FOR MULTIPLE SCLEROSIS |
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity |
|
CBD FOR MULTIPLE SCLEROSIS |
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors |
|
CBD FOR MULTIPLE SCLEROSIS |
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial |
|
CBD FOR MULTIPLE SCLEROSIS |
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis |
|
CBD FOR MULTIPLE SCLEROSIS |
Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis |
|
CBD FOR MULTIPLE SCLEROSIS |
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis |
|
CBD FOR MULTIPLE SCLEROSIS |
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain( |
|
CBD FOR MULTIPLE SCLEROSIS |
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain |
|
CBD FOR NAUSEA |
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation |
|
CBD FOR NAUSEA |
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews |
|
CBD FOR NAUSEA |
Regulation of nausea and vomiting by cannabinoids |
|
CBD FOR NAUSEA |
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats |
|
CBD FOR NAUSEA |
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting |
|
CBD FOR NEURODEGENERATION |
Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? |
|
CBD FOR NEURODEGENERATION |
Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder |
|
CBD FOR NEURODEGENERATION |
Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders |
|
CBD FOR NEURODEGENERATION |
Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection |
|
CBD FOR NEUROPATHIC PAIN |
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain |
|
CBD FOR NEUROPATHIC PAIN |
Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine |
|
CBD FOR NEUROPATHIC PAIN |
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial |
|
CBD FOR NEUROPATHIC PAIN |
Cannabinoids for neuropathic pain |
|
CBD FOR NEUROPATHIC PAIN |
Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue |
|
CBD FOR NEUROPATHIC PAIN |
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial |
|
CBD FOR NEUROPATHIC PAIN |
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain |
|
CBD FOR NEUROPATHIC PAIN |
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation |
|
CBD FOR NEUROPATHIC PAIN |
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy |
|
CBD FOR NEUROPATHIC PAIN |
Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved |
|
CBD FOR NEUROPATHIC PAIN |
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action |
|
CBD FOR NEUROPATHIC PAIN |
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors |
|
CBD FOR NEUROPATHIC PAIN |
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes |
|
CBD FOR NEUROPATHIC PAIN |
Cannabinoids in the management of difficult to treat pain |
|
CBD FOR NEUROPATHIC PAIN |
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain |
|
CBD FOR NEUROPATHIC PAIN |
Marijuana extract helps prevent chemo pain |
|
CBD FOR NEUROPATHIC PAIN |
Pot users less likely to take painkillers |
|
CBD FOR OBESITY |
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns |
|
CBD FOR OBESITY |
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? |
|
CBD FOR OBESITY |
The endocannabinoid system in obesity and type 2 diabetes |
|
CBD FOR OBESITY |
Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk |
|
CBD FOR OBESITY |
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes |
|
CBD FOR OCD |
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour |
|
CBD FOR OCD |
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice |
|
CBD FOR PARKINSONS DISEASE |
Prospects for cannabinoid therapies in basal ganglia disorders |
|
CBD FOR PARKINSONS DISEASE |
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties |
|
CBD FOR PARKINSONS DISEASE |
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease |
|
CBD FOR PARKINSONS DISEASE |
Cannabidiol for the treatment of psychosis in Parkinson’s disease |
|
CBD FOR PARKINSONS DISEASE |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease |
|
CBD FOR PARKINSONS DISEASE |
Therapeutic potential of cannabinoids in CNS disease |
|
CBD FOR PRION |
Cannabidiol: A prion therapy for mice? |
|
CBD FOR PRION |
Alteration of the endocannabinoid system in mouse brain during prion disease |
|
CBD FOR PTSD |
Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks |
|
CBD FOR PTSD |
Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear |
|
CBD FOR PTSD |
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors |
|
CBD FOR PTSD |
Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis |
|
CBD FOR PTSD |
Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence |
|
CBD FOR PTSD |
Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment |
|
CBD FOR PTSD |
The endocannabinoid system and extinction learning |
|
CBD FOR PTSD |
A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers |
|
CBD FOR PTSD |
Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit |
|
CBD FOR PTSD |
Non-antidepressant long-term treatment in post-traumatic stress disorder |
|
CBD FOR PTSD |
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system |
|
CBD FOR PTSD |
Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors |
|
CBD FOR RHEUMATISM |
Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases |
|
CBD FOR RHEUMATISM |
Clinical Implications for Cannabinoid Use in the Rheumatic Diseases |
|
CBD FOR RHEUMATISM |
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases |
|
CBD FOR SCHIZOPHRENIA |
Cannabidiol as a potential treatment for psychosis |
|
CBD FOR SCHIZOPHRENIA |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia |
|
CBD FOR SCHIZOPHRENIA |
Medical use of cannabis. Cannabidiol: A new light for schizophrenia? |
|
CBD FOR SCHIZOPHRENIA |
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation |
|
CBD FOR SCHIZOPHRENIA |
Peripheral endocannabinoid system dysregulation in first-episode psychosis |
|
CBD FOR SCHIZOPHRENIA |
Cannabinoids and schizophrenia: Therapeutic prospects |
|
CBD FOR SCHIZOPHRENIA |
Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies |
|
CBD FOR SCHIZOPHRENIA |
Cannabidiol monotherapy for treatment-resistant schizophrenia |
|
CBD FOR SCHIZOPHRENIA |
Cannabis with high cannabidiol content is associated with fewer psychotic experiences |
|
CBD FOR SCHIZOPHRENIA |
Marijuana compound treats schizophrenia with few side effects: Clinical trial |
|
CBD FOR SCHIZOPHRENIA |
Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia? |
|
CBD FOR SICKLE CELL ANEMIA |
Cannabis use in sickle cell disease: A questionnaire study |
|
CBD FOR SICKLE CELL ANEMIA |
Cannabinoid Receptor-Specific Mechanisms To Alleviate Pain In Sickle Cell Anemia Via Inhibition Of Mast Cell Activation And Neurogenic Inflammation |
|
CBD FOR SKIN CONDITIONS |
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes |
|
CBD FOR SKIN CONDITIONS |
The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities |
|
CBD FOR SKIN CONDITIONS |
Epigenetic control of skin differentiation genes by phytocannabinoids |
|
CBD FOR SKIN CONDITIONS |
Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1 |
|
CBD FOR SKIN CONDITIONS |
Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation |
|
CBD FOR SKIN CONDITIONS |
Attenuation of allergic contact dermatitis through the endocannabinoid system |
|
CBD FOR SKIN CONDITIONS |
Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus |
|
CBD FOR SLEEP DISORDERS |
Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine |
|
CBD FOR SLEEP DISORDERS |
Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats |
|
CBD FOR SLEEP DISORDERS |
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults |
|
CBD FOR SLEEP DISORDERS |
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats |
|
CBD FOR SLEEP DISORDERS |
Endocannabinoid modulation of cortical up-states and NREM sleep |
|
CBD FOR SLEEP DISORDERS |
Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat |
|
CBD FOR SPINAL CORD INJURY |
Cannabis effect on spasticity in spinal cord injury |
|
CBD FOR SPINAL CORD INJURY |
An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease |
|
CBD FOR SPINAL CORD INJURY |
Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury |
|
CBD FOR STRESS |
Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders |
|
CBD FOR STRESS |
Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output |
|
CBD FOR STRESS |
Neuromodulators, stress and plasticity: a role for endocannabinoid signalling |
|
CBD FOR STRESS |
Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress |
|
CBD FOR STRESS |
Endocannabinoids and stress |
|
CBD FOR STRESS |
Stress regulates endocannabinoid-CB1 receptor signaling |
|
CBD FOR STRESS |
Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus |
|
CBD FOR STRESS |
Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance |
|
CBD FOR STRESS |
Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression |
|
CBD FOR STRESS |
Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory |
|
CBD FOR STRESS |
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system |
|
CBD FOR STRESS |
Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid |
|
CBD FOR STROKE/TBI |
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism |
|
CBD FOR STROKE/TBI |
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism ( |
|
CBD FOR STROKE/TBI |
Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function |
|
CBD FOR STROKE/TBI |
Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice |
|
CBD FOR STROKE/TBI |
Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance |